Martingale Asset Management L P Arcutis Biotherapeutics, Inc. Transaction History

Martingale Asset Management L P

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$10.23 - $17.14 $37,851 - $63,418	3,700 Added 8.56%	46,904 $515,000
Q4 2022 Feb 13, 2023	BUY	$13.96 - $20.4 $224,700 - $328,358	16,096 Added 59.38%	43,204 $639,000
Q3 2022 Nov 14, 2022	BUY	$17.85 - $26.95 $483,877 - $730,560	27,108 New	27,108 $519,000
Q1 2022 May 12, 2022	SELL	$14.38 - $22.79 $332,336 - $526,699	-23,111 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$14.98 - $25.5 $169,393 - $288,354	11,308 Added 95.81%	23,111 $479,000

Q3 2021 Nov 12, 2021	BUY	$19.28 - $27.1 $227,561 - $319,861	11,803 New	11,803 $281,000
Q2 2021 Aug 13, 2021	SELL	$24.42 - $34.75 $176,019 - $250,478	-7,208 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$24.47 - $36.98 $176,379 - $266,551	7,208 New	7,208 $208,000

172

126M

498K

1.64M

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $560M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.